Počet záznamov: 1
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'
SYS 0148615 LBL 00000naa^^22^^^^^^^^450 005 20180920124044.6 100 $a 20180815d2018 m y0sloy0103 ba 101 0-
$a eng 102 $a SK 200 1-
$a Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE' $f Šufliarsky J. ... [et al.] 305 $a Annals of oncology, May 5 (2018) 463 -1
$1 001 sllk_un_cat*0147827 $1 011 $a 1336-8176 $1 200 1 $a Onkológia $v Roč. 13, č. 3 (2018), s. 222 $1 210 $a Bratislava $c SOLEN $d 2018 $1 215 $a s. 157-226 606 1-
$3 sllk_un_auth*d018227 $a sarkóm svetlobunkový $x farmakoterapia $2 mesh 610 2-
$a krizotinib 701 -1
$3 sllk_un_auth*p0050766 $a Šufliarsky $b Jozef $p Národný onkologický ústav, Bratislava $4 100 711 02
$3 sllk_un_auth*0012742 $a Redakcia Onkológia $4 010 801 -0
$a SK $b BA006 $c 20180815 $g AACR2
Počet záznamov: 1